Extract to table

This input is particularly important for products intended for simultaneous or sequential global regulatory submissions, where differences in regulatory requirements across jurisdictions must be addressed during trial design rather than retrospectively

• Health technology assessment ("HTA") requirements (whereby PBI must demonstrate the clinical and economic value of its products to HTA bodies in order to obtain favorable reimbursement and pricing)